MX2021014913A - Compuestos de pirrolidina. - Google Patents

Compuestos de pirrolidina.

Info

Publication number
MX2021014913A
MX2021014913A MX2021014913A MX2021014913A MX2021014913A MX 2021014913 A MX2021014913 A MX 2021014913A MX 2021014913 A MX2021014913 A MX 2021014913A MX 2021014913 A MX2021014913 A MX 2021014913A MX 2021014913 A MX2021014913 A MX 2021014913A
Authority
MX
Mexico
Prior art keywords
sub
och
compounds
formula
pyrrolidine compounds
Prior art date
Application number
MX2021014913A
Other languages
English (en)
Inventor
Buezo Nuria Diaz
Blanco Celia Lafuente
Perez Jose Antonio Martinez
Gil Gema Consuelo Sanz
Soler Julian Priego
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021014913A publication Critical patent/MX2021014913A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (ver Fórmula) en donde L se selecciona del grupo que consiste en -CH2NHCH2-, -CH2NH-, -NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, -NHSO2NH-, (ver Fórmulas) o una sal farmacéuticamente aceptable de estos; un compuesto de la fórmula: (ver Fórmula), procesos para preparar los compuestos y sus sales, una composición farmacéutica y métodos para tratar pacientes que necesiten dicho tratamiento.
MX2021014913A 2019-06-07 2020-06-03 Compuestos de pirrolidina. MX2021014913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382477 2019-06-07
PCT/US2020/035825 WO2020247429A1 (en) 2019-06-07 2020-06-03 Pyrrolidine compounds

Publications (1)

Publication Number Publication Date
MX2021014913A true MX2021014913A (es) 2022-01-18

Family

ID=66821161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014913A MX2021014913A (es) 2019-06-07 2020-06-03 Compuestos de pirrolidina.

Country Status (24)

Country Link
US (2) US11286249B2 (es)
EP (1) EP3980409A1 (es)
JP (3) JP6940717B2 (es)
KR (2) KR102477481B1 (es)
CN (1) CN114008021A (es)
AU (1) AU2020287599B2 (es)
BR (1) BR112021023347A2 (es)
CA (1) CA3140869A1 (es)
CL (1) CL2021003202A1 (es)
CO (1) CO2021016295A2 (es)
CR (1) CR20210602A (es)
DO (1) DOP2021000254A (es)
EA (1) EA202193007A1 (es)
EC (1) ECSP21088515A (es)
IL (1) IL288174A (es)
JO (1) JOP20210319A1 (es)
MA (1) MA56115A (es)
MX (1) MX2021014913A (es)
PE (1) PE20220134A1 (es)
SA (1) SA521431048B1 (es)
SG (1) SG11202113244UA (es)
UA (1) UA128540C2 (es)
WO (1) WO2020247429A1 (es)
ZA (1) ZA202109251B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022381258A1 (en) 2021-11-03 2024-05-02 Tuojie Biotech (Shanghai) Co., Ltd. Substituted phenylpropionic acid derivative and use thereof
AU2023212015A1 (en) 2022-01-26 2024-07-18 Eli Lilly And Company Pyrrolidine compounds
WO2024199070A1 (zh) * 2023-03-24 2024-10-03 上海京新生物医药有限公司 一种环状胺衍生物及其组合物与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452521A4 (en) * 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR
BR0318685A (pt) 2003-12-24 2006-12-19 Esperion Therapeutics Inc compostos de cetona e composições para controle de colesterol e usos relacionados
WO2005068410A1 (en) * 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
CN112321475B (zh) 2020-11-13 2022-06-10 四川大学 一种γ-氨基酸类似物及其合成方法

Also Published As

Publication number Publication date
KR20220018494A (ko) 2022-02-15
WO2020247429A1 (en) 2020-12-10
DOP2021000254A (es) 2022-01-16
IL288174A (en) 2022-01-01
AU2020287599B2 (en) 2023-10-19
ZA202109251B (en) 2024-04-24
KR102477481B1 (ko) 2022-12-15
US20220169636A1 (en) 2022-06-02
CO2021016295A2 (es) 2021-12-10
CR20210602A (es) 2022-01-06
EP3980409A1 (en) 2022-04-13
SA521431048B1 (ar) 2024-04-28
JP2021524498A (ja) 2021-09-13
AU2020287599A1 (en) 2022-01-06
BR112021023347A2 (pt) 2022-04-12
MA56115A (fr) 2022-04-13
CA3140869A1 (en) 2020-12-10
ECSP21088515A (es) 2022-01-31
SG11202113244UA (en) 2021-12-30
US20210253559A1 (en) 2021-08-19
JP7508422B2 (ja) 2024-07-01
UA128540C2 (uk) 2024-08-07
JP2021191784A (ja) 2021-12-16
US11286249B2 (en) 2022-03-29
JOP20210319A1 (ar) 2023-01-30
KR102629923B1 (ko) 2024-01-30
JP6940717B2 (ja) 2021-09-29
PE20220134A1 (es) 2022-01-27
CL2021003202A1 (es) 2022-09-09
EA202193007A1 (ru) 2022-03-25
CN114008021A (zh) 2022-02-01
KR20240014618A (ko) 2024-02-01
KR20230004890A (ko) 2023-01-06
JP2024123111A (ja) 2024-09-10

Similar Documents

Publication Publication Date Title
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2021014913A (es) Compuestos de pirrolidina.
CR20210627A (es) Derivados de benzisoxazol sulfonimada
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MX2023007192A (es) Inhibidores de prmt5.
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2024000299A (es) Compuestos antivirales.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2023002547A (es) Compuestos novedosos como inhibidor de histona desacetilasa 6 y composicion farmaceutica que comprende los mismos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2021014458A (es) Compuestos triciclicos.
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
SE0201837D0 (sv) Chemical compounds
MX2024000028A (es) Piridin-1,5-dionas espirocíclicas que exhiben inhibición de la proteína cinasa activada por mitógenos (mnk) y su método de uso.
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
MX2023009166A (es) Derivados de quinoxalina y sus usos.